 |
|
 |
|
| MarketVIEW: Clostridium difficile vaccines |
|
|
|
Updated: January 2014
Clostridium difficile (C.diff) is a Gram-positive bacterium, which in vulnerable hospitalized patients can cause gastrointestinal infections (CDI). Outcomes range from mild uncomplicated diarrhea to severe-complicated disease where patients experience fever,
tachycardia and psuedomembranous colitis. Risk factors for C.diff infections are >65 yrs of age, hospitalization, severe underlying illness coupled with chronic antibiotic therapy.
Although CDAD can be managed usually by stopping antibiotic therapy or the use of metronidazole and vancomycin treatment, patient mortality can still reach 6-30%.
In some patients with toxic megacolon who require surgical intervention or colectomy, mortality can reach even higher rates of 35-50%.
This MarketVIEW product is a comprehensive commercial opportunity assessment which forecasts the potential of C.DIFF vaccines to 2030 in the major Western markets. All potential vaccine indications are modelled: with a focus on key target populations as defined by the enrolment criteria of the Sanofi phase 3 CDIFFENSE trial. Also included is an in-depth epidemiology forecast to 2030 including number of CDI cases per country drawing upon latest surveillance data (pan-European survey). A discussion of the potential cost effectiveness implications of the vaccine is included along with an up-to-date review of competitor programs and preclinical activity.
THIS PRODUCT IS AN EXECUTIVE PRESENTATION + 1 MODEL
To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW.
For UK orders VAT will be added at 20%.
Please review the TERMS and CONDITIONS of purchase.
|
|
|
|
|
|
